Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Published byLuz Lara Lucero Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus."— Presentation transcript:

1 Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus
Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus. These statements are in part based on the reported European NAFLD guidelines99,100. *Biomarkers have been well-studied to detect steatosis and fibrosis in NAFLD and have value in guiding clinical management. HbA1c, glycated haemoglobin; HOMA-IR, homeostatic model assessment of insulin resistance; OGTT, oral glucose tolerance test; T2DM, type 2 diabetes mellitus. Tilg, H. et al. (2016) NAFLD and diabetes mellitus Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Download ppt "Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus."

Similar presentations

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD Featured Article: Jessica Bazick,

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD Featured Article: Jessica Bazick,
Figure 1 Proposed risk stratification for patients with NAFLD

Figure 1 Proposed risk stratification for patients with NAFLD
Independent variables (baseline) Loge (HOMA-IR) b P

Independent variables (baseline) Loge (HOMA-IR) b P
Copyright © 2017 American Academy of Pediatrics.

Copyright © 2017 American Academy of Pediatrics.
Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.

Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.
Figure 2 Inflammatory pathways affecting hepatic insulin resistance

Figure 2 Inflammatory pathways affecting hepatic insulin resistance
Figure 2 Pathophysiology of hyperglycaemia in T2DM

Figure 2 Pathophysiology of hyperglycaemia in T2DM
with undiagnosed diabetes mellitus by three diagnostic criteria

with undiagnosed diabetes mellitus by three diagnostic criteria
Figure 4 Activation of clopidogrel via cytochrome P450

Figure 4 Activation of clopidogrel via cytochrome P450
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
How to Approach a Patient With Nonalcoholic Fatty Liver Disease

How to Approach a Patient With Nonalcoholic Fatty Liver Disease
Figure 1 Pathophysiological aspects of insulin

Figure 1 Pathophysiological aspects of insulin
Figure 2 A stage-based approach to the treatment of NAFLD

Figure 2 A stage-based approach to the treatment of NAFLD
Figure 5 Lipid droplet consumption

Figure 5 Lipid droplet consumption
Figure 1 Worldwide incidence of CCA

Figure 1 Worldwide incidence of CCA
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Biosimilar development process

Figure 1 Biosimilar development process
Figure 5 Risk factor control in the intensive treatment group

Figure 5 Risk factor control in the intensive treatment group
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Similar presentations

Ads by Google